Study on 68Gallium-FAPI PET/CT Imaging for Patients with Chronic Inflammatory Disorders Using Gallium (68Ga) Chloride and 68-FAPI-46

2 1 1 1

What is this study about?

This clinical trial is focused on studying various chronic inflammatory and fibrotic diseases. These are conditions where the body’s immune system causes long-term inflammation and scarring in tissues. The study will use a special imaging technique called PET/CT to look at these diseases. The imaging involves a radioactive tracer called 68-FAPI-46, which is injected into the body. This tracer helps to highlight areas of inflammation and fibrosis during the scan.

The purpose of the study is to observe and describe how the tracer behaves in the body and how it highlights different areas affected by the diseases. The study will involve a single injection of the tracer, followed by a PET/CT scan to capture images of the affected areas. This will help researchers understand the intensity and location of the disease activity in the body.

The study will take place over a period of time, with participants undergoing the imaging process at the start of the study. The information gathered from these images will be used to better understand the diseases and potentially improve future treatments. The study aims to provide valuable insights into how these diseases affect the body and how they can be better managed in the future.

1 initial assessment

Upon joining the study, eligibility is confirmed based on criteria such as age (18 or over) and diagnosis of a relevant chronic inflammatory or fibrotic disease.

A comprehensive review of medical history and current health status is conducted to ensure alignment with study requirements.

2 preparation for imaging

Preparation involves understanding the procedure for the 68Gallium-FAPI PET/CT imaging, which is used to assess inflammation and fibrosis in the body.

Instructions are provided regarding any necessary dietary or medication adjustments prior to the imaging session.

3 administration of tracer

The tracer, 68Ga-FAPI-46, is administered as an injectable solution. This tracer helps in visualizing specific areas of inflammation or fibrosis during the imaging process.

The injection is performed under controlled conditions to ensure safety and accuracy.

4 PET/CT imaging

The PET/CT scan is conducted to capture detailed images of the body, highlighting areas where the tracer accumulates.

The scan provides information on the intensity and location of tracer uptake, which is crucial for evaluating the condition.

5 data analysis

The images obtained from the PET/CT scan are analyzed to measure the binding intensity using a standardized uptake value (SUV) max.

This analysis helps in understanding the extent and nature of the inflammatory or fibrotic process.

6 follow-up assessments

Additional assessments may be conducted to measure specific scores related to the pathology, such as reference scores, biomarkers, and functional parameters.

These assessments help in providing a comprehensive evaluation of the disease and its progression.

7 completion of study participation

The study is expected to conclude by October 21, 2026, with recruitment starting on October 1, 2024.

Participants may be required to attend follow-up visits or provide additional information as part of the study’s final assessments.

Who Can Join the Study?

  • Patient aged 18 or over
  • Affected by one of the conditions being studied
  • Meeting the agreed-upon classification criteria for the condition
  • Fitting the specific clinical situation related to the study

Who Cannot Join the Study?

  • Individuals with certain inflammatory disorders cannot participate. Inflammatory disorders are conditions where parts of the body become swollen, red, and painful.
  • Participants must be within specific age ranges, which are not specified here.
  • Both male and female participants are eligible, but certain criteria may exclude some individuals.
  • Individuals considered part of a vulnerable population are not included. Vulnerable populations are groups that may need special protection, like children or the elderly.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Centre Hospitalier Regional Et Universitaire De Brest Brest France

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
01.10.2024

Trial locations

68Gallium-FAPI is a radiotracer used in PET/CT imaging. It helps in identifying and visualizing areas of inflammation and fibrosis in the body. This medication is particularly useful in detecting chronic inflammatory and fibrotic diseases by highlighting the affected tissues during the imaging process.

Investigated diseases:

Rheumatoid Arthritis – Rheumatoid arthritis is a chronic inflammatory disorder that primarily affects the joints. It typically causes swelling, pain, and stiffness, often in the hands and feet. Over time, it can lead to joint damage and deformities. The disease progresses through periods of flares and remissions. It can also affect other parts of the body, including the skin, eyes, and lungs. The exact cause is unknown, but it involves the immune system attacking the body’s own tissues.

Systemic Lupus Erythematosus – Systemic lupus erythematosus is an autoimmune disease where the immune system attacks healthy tissues. It can affect the skin, joints, kidneys, brain, and other organs. Symptoms vary widely but often include fatigue, joint pain, and skin rashes. The disease can progress with periods of increased activity, known as flares, and times of remission. The exact cause is not fully understood, but it involves genetic and environmental factors. It is more common in women than men.

Sarcoidosis – Sarcoidosis is an inflammatory disease characterized by the formation of small clumps of inflammatory cells, called granulomas, in various organs. It most commonly affects the lungs and lymph nodes but can involve any organ. Symptoms can include cough, shortness of breath, and fatigue. The progression of sarcoidosis varies; it can resolve on its own or become chronic. The cause of sarcoidosis is unknown, but it is thought to involve an abnormal immune response. It can affect people of any age, but it is more common in adults.

Idiopathic Pulmonary Fibrosis – Idiopathic pulmonary fibrosis is a chronic lung disease that results in scarring of the lung tissue. This scarring makes it difficult for the lungs to work properly, leading to symptoms like shortness of breath and a persistent dry cough. The disease progresses over time, with lung function gradually declining. The cause of idiopathic pulmonary fibrosis is unknown, but it is believed to involve genetic and environmental factors. It primarily affects older adults. The progression rate can vary significantly among individuals.

Scleroderma – Scleroderma is a group of autoimmune diseases that cause hardening and tightening of the skin and connective tissues. It can affect only the skin or involve internal organs, such as the heart, lungs, and kidneys. Symptoms include skin thickening, joint pain, and digestive issues. The disease progresses differently in each person, with some experiencing mild symptoms and others having severe complications. The exact cause is unknown, but it involves the immune system attacking the body’s own tissues. It is more common in women than men.

Trial ID:
2023-508190-84-01
Protocol code:
29BRC23.0029
NCT ID:
NCT06275477
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of 18F-AlF-FAPI-74 PET/CT imaging compared to standard 18F-FDG PET/CT in patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis

    Recruiting

    4 1 1
    Investigated drugs:
    Belgium
  • Study on Stopping Prednisone for Patients with Inflammatory or Autoimmune Disorders

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany